Skip to content
Screener

PTC Therapeutics PTCT Business Segments — Manufacturing Costs

Similar metrics at other companies

Vishay Intertechnology logo
VSHManufacturing Costs
$681.19M+11.0%
Luxfer Holdings logo
LXFRElektron — Manufacturing Costs
$8.6M+3.6%
Luxfer Holdings logo
LXFRSuperform — Manufacturing Costs
$200K-33.3%
Nuvectis Pharma, Inc. logo
NVCTClinical Development — Manufacturing Costs
$829K+74.2%
Luxfer Holdings logo
LXFRGas Cylinders — Manufacturing Costs
$6.6M-13.2%
Pulse Biosciences, Inc. logo
PLSESingle Reportable — Manufacturing Costs
$3.2M+8.8%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×
P/S+4.7×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ManufacturingCosts.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Cost of product, collaboration and license sales19,6797,707
Program spend37,54448,158
Employee costs76,12167,699
Manufacturing costs9,08514,950
Administrative costs16,68818,414
Occupancy costs8,3547,183
Other segment items (a)107,889145,423
Segment net (loss) income$(2,809)$866,562

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's business segments — manufacturing costs?
PTC Therapeutics (PTCT) reported business segments — manufacturing costs of $9.09M in Q1 2026.
How has PTC Therapeutics's business segments — manufacturing costs changed year-over-year?
PTC Therapeutics's business segments — manufacturing costs decreased by 39.2% year-over-year, from $14.95M to $9.09M.
What is the long-term trend for PTC Therapeutics's business segments — manufacturing costs?
Over 3 years (2022 to 2025), PTC Therapeutics's business segments — manufacturing costs has grown at a -14.6% compound annual growth rate (CAGR), from $108.03M to $67.32M.
What does business segments — manufacturing costs mean?
This encompasses the operational expenses incurred in the production, quality control, and supply chain management of pharmaceutical products. Monitoring this metric helps assess the scalability and cost-efficiency of the company's manufacturing processes.

Ask your AI about PTC Therapeutics's business segments — manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude